Pharmacokinetic modeling
![Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)
Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain
... ent pharmacokinetic models for rat studies. Nonetheless, pharmacokinetic modeling can be of particular relevance in the pre-clinical setting, since animal studies are often applied in drug ...
12
Pharmacokinetic modeling of a novel hypoxia PET tracer [18F]HX4 in patients with non-small cell lung cancer
... with pharmacokinetic modeling results published for the hypoxia tracer [ 18 F]FAZA [27], which, like [ 18 F]HX4, is relatively hydrophilic compared to [ 18 ...
12
Compartmentalizing the Sunlight Vitamin: Physiologically Based Pharmacokinetic Modeling and Vitamin D.
... biological background of vitamin D and its metabolic cascade. A significant portion of this chapter is devoted to the enzymes involved in the pathway; understanding the complexities of the pathway is the key to ...
140
Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass
... When comparing the PK parameters of acetaminophen in children after cardiac surgery with cardiopulmonary bypass with those from chil- dren of the same age following noncardiac surgery re[r] ...
10
Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling
... pediatric pharmacokinetic models for vancomycin were externally evaluated and subsequently used to derive model-based dosing algorithms for neonates, infants, and ...published pharmacokinetic models were ...
9
Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach
... ects modeling approach using available individual human plasma data (Table 1), since there is no plasma PK model from literature or the existing plasma PK model did not adequately describe the data (Yamamoto et ...
13
Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics
... Development, calibration, and validation of PBPK models for nanoparticles require reliable and relevant experimental data that provide information about properties of nanopar- ticles as well as quantities in several ...
16
<p>Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population</p>
... Objective: The main aim of this analysis was to characterize the pharmacokinetics (PK) of the strong analgesic tapentadol in 2-year-old to <18-year-old patients with acute pain and to inform the optimal dosing ...
16
Physiologically based pharmacokinetic modeling of zinc oxide nanoparticles and zinc nitrate in mice
... Abstract: Zinc oxide nanoparticles (ZnO NPs) have been widely used in consumer products, therapeutic agents, and drug delivery systems. However, the fate and behavior of ZnO NPs in living organisms are not well ...
16
Population pharmacokinetic modeling of flurbiprofen, the active metabolite of flurbiprofen axetil, in Chinese patients with postoperative pain
... Potential covariates of age, sex, body weight, height, and BMI were tested for PK parameters. The categorical covariate (sex) was incorporated using indicator variables with an exponential function. Influences of ...
10
Diagnostics for nonlinear models with application to population pharmacokinetic modeling
... diagnosing pharmacokinetic (PK) models by visualizing re- sampling statistics, such as case deletion and ...Population pharmacokinetic (PopPK) modeling targets the dose-concentration effect of ...
187
Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
... PBPK modeling, the concentration-time profiles of both the inhibitor and substrate drugs including the metabolites, the inhibition potency of the inhibitor, and the percentage metabolism of the substrate by the ...
14
Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content
... PBPK modeling to interpret the effects of multiple nanoparticle properties on their ...PBPK modeling approach for the building of nanoparticle property-distribution relation- ships in ...
12
Pharmacokinetic Modeling of Ceftiofur Sodium
... Individual predictions of CEF equivalent plasma concentrations in healthy beagle dogs from the final. 199[r] ...
12
Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects
... a pharmacokinetic model since the majority of subjects (19) did not show EHC, and also because there were not enough data points to fully characterize the EHC ...
10
QUANTITATIVE STRUCTURE PHARMACOKINETIC RELATIONSHIP USING ARTIFICIAL NEURAL NETWORK: A REVIEW
... of pharmacokinetic parameters in quantitative drug ...of pharmacokinetic parameters. Physiologically based pharmacokinetic modeling describes the whole body by a number of anatomical ...
10
Defining medication adherence in individual patients
... Methods: We used pharmacokinetic modeling to calculate serum drug levels in patients whose patterns of dosing were recorded by a medication event monitoring system. Medication event monitoring system data ...
5
Comparative Pharmacokinetic Approaches to Estimating the Pharmacokinetics of Water Medications in Swine
... few pharmacokinetic studies have been conducted on water medications in general (2, 20, ...adequately modeling the pharmacokinetics of the drug ...improved pharmacokinetic modeling is ...
138
Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers
... The characters of PK behaviors and its influences to the values of plasma glucose levels have been studied in several hypoglycemic drugs [23, 24]. Toshiyuki Takanohashi et al. reported the pk-pd. modeling ...
8
Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
... obtained from all the study participants, and the study was approved by The Biomedical Research Ethics Committee of the University of Durban- Westville. Twenty-four subjects with type 2 diabetes were entered into a ...
13